(Total Views: 99)
Posted On: 02/07/2025 1:42:36 PM
Post# of 36177
$DYAI Looking Toward Product Revenues
Dyadic International Inc. (NASDAQ
YAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin and bovine alpha-lactalbumin. Dyadic’s partner is expected to first focus on research grade product, but will be able to expand into the excipient grade and current good manufacturing practices (cGMP) grade product as the market matures.
https://finance.yahoo.com/news/dyai-looking-t...00269.html
Dyadic International Inc. (NASDAQ
YAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin and bovine alpha-lactalbumin. Dyadic’s partner is expected to first focus on research grade product, but will be able to expand into the excipient grade and current good manufacturing practices (cGMP) grade product as the market matures. https://finance.yahoo.com/news/dyai-looking-t...00269.html
(0)
(0)
